Icatibant
๐ Icatibant acetate (Firazyrยฎ) is recommended for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents, and children โฅ2 years with C1 esterase-inhibitor deficiency.
๐ About
- ๐ Always refer to the BNF or equivalent for up-to-date prescribing advice before use.
โ๏ธ Mode of Action
- ๐งฌ Icatibant is a selective bradykinin B2 receptor antagonist.
- โ Blocks bradykinin โ prevents โ vascular permeability โ reduces angioedema.
๐ Indication & Dose
- Indication: Acute attacks of HAE due to C1-INH deficiency.
- Dosage: Adults & adolescents โ 30 mg SC (1 syringe).
โก๏ธ If needed, repeat after 6 hours.
โ ๏ธ Max: 3 doses in 24 hours.
๐ Interactions
- โ ๏ธ Always consult the BNF โ interactions vary depending on comorbidities & concurrent meds.
โ ๏ธ Cautions
- Use carefully in patients with history of ischaemic heart disease or stroke โ possible cardiovascular effects.
โ Contraindications
- Known hypersensitivity to Icatibant or excipients (see BNF for full list).
๐ฅ Side Effects
- Common: dizziness, fever, headache, nausea.
- Injection site reactions (pain, swelling, erythema) are very common.
๐ UK Exam Pearls
- ๐ Icatibant is not an antihistamine or steroid โ HAE is bradykinin-mediated, not histamine-mediated.
- ๐ก Distinguish from allergy: urticaria is absent in HAE.
- ๐ฉโโ๏ธ First-line in UK/EU for acute HAE attacks โ rapid SC self-injection possible at home.
- ๐ If laryngeal involvement โ airway protection takes priority, alongside Icatibant/ C1-INH.
- ๐ฌ๐ง In UK exams, Icatibant + C1-INH concentrate are the key acute therapies for HAE.
๐ References
๐ Revisions
- Draft updated with exam pearls (2025).